GLP-1 and incretin compared

Oral semaglutide vs orforglipron

A GLP-1 analogue peptide in a tablet and a small-molecule GLP-1 receptor agonist, with each figure tied to its own label or trial.

Oral semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1, and orforglipron is a small-molecule, nonpeptide oral GLP-1 receptor agonist.1,2 The US labels give semaglutide an elimination half-life of about one week and orforglipron about 29 to 49 hours after an oral dose.1,3

Semaglutide tablets are labelled in the US for glycemic control in type 2 diabetes and, as Wegovy tablets, for weight reduction, and both labels also cover reducing the risk of major cardiovascular events; orforglipron is labelled as Foundayo for weight reduction in adults with obesity or with overweight and a weight-related condition.1,4,3

FactOral SemaglutideOrforglipron
What it isA GLP-1 analogue with 94% sequence homology to human GLP-1, in tablets co-formulated with SNAC to aid absorption1A small-molecule, nonpeptide GLP-1 receptor agonist taken by mouth2,3
How it comesTablets: Rybelsus 3, 7 or 14 mg and Ozempic tablets 1.5, 4 or 9 mg1; Wegovy tablets with a 25 mg daily maintenance dosage4Foundayo tablets for oral use, taken once daily with or without food3
Half-lifeAbout one week on the US label; present in the circulation for about five weeks after the last tablet1
  • About 29 to 49 hours after an oral dose, on the US label3
  • 24.6 to 35.3 hours after a single dose and 48.1 to 67.5 hours on day 28, in a phase 1a study5
Studied doses
  • US label (Rybelsus): 3 mg once daily to start, 7 mg from day 31, 14 mg if more glycemic control is needed1
  • Obesity trial: 25 mg or placebo once daily, randomised 2:1, results at week 646
  • US label: 0.8 mg once daily to start, raised after at least 30 days on each dosage, to a maximum of 17.2 mg3
  • Obesity trial: 6, 12 or 36 mg of an investigational formulation, shown on the label as 5.5, 9 or 17.2 mg of Foundayo, or placebo, once daily for 72 weeks2,3
StatusUS labels: glycemic control in adults with type 2 diabetes1, and weight reduction as Wegovy tablets4, and to reduce the risk of major cardiovascular events1,4. EU: Rybelsus first authorised on 3 April 20207US label (first approved 2026): weight reduction and its long-term maintenance in adults with obesity, or overweight with a weight-related condition3

Get the app

Contents6
  1. 1How they differ
  2. 2Levels after one dose
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

How they differ

The semaglutide tablet label gives an absolute bioavailability of 0.4% to 1% for the Rybelsus strengths and 1% to 2% for Ozempic tablets, and the Foundayo label 77% after a 0.8 mg dose.1,3 Semaglutide absorption occurs mainly in the stomach and peaks about 1 hour after a tablet, while orforglipron peaks 4 to 8 hours after a dose and the Foundayo label reports no clinically relevant food effect.1,3

The Foundayo label states that orforglipron is metabolized primarily by hepatic CYP3A4.3

Levels after one dose

Oral Semaglutide and orforglipron after one dose, each as a share of that dose. Each curve follows the half-life its compound page draws, from the Milligram app's model; the sourced half-lives are in the facts table.

Logged in Milligram

  • Oral Semaglutide: Too few people logged it to show a share.
  • Orforglipron: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The semaglutide tablet label states that it is unknown whether the tablets cause thyroid C-cell tumors in humans, and the Foundayo label states that the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors in rodents has not been determined.1,3 The Foundayo label presents its efficacy data from an investigational orforglipron formulation, shown as equivalent Foundayo dosages, and the Wegovy label states that the tablets have not been studied for weight reduction in adults with type 2 diabetes.3,4

References

  1. Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (oral semaglutide) label, version 14. US label (DailyMed), 2026. DailyMed label
  2. Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Journal article (PubMed), 2025. PMID 40960239
  3. Eli Lilly and Company. FOUNDAYO (orforglipron) label, version 10. US label (DailyMed), 2026. DailyMed label
  4. Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) label, version 19. US label (DailyMed), 2026. DailyMed label
  5. Pratt E, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Journal article (PubMed), 2023. PMID 37344954
  6. Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Journal article (PubMed), 2025. PMID 40934115
  7. European Medicines Agency. Rybelsus: summary of product characteristics. EU product information, 2026. ema.europa.eu